Integer Holdings Corp

ITGR

Equity

ISIN null / Valor 33080752

New York Stock Exchange, Inc (2026-04-06)

USD 85.63-1.40%

Integer Holdings Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Integer Holdings Corp is a leading medical device technology company that designs and manufactures a wide range of products, including catheters, guidewires, implantable ports, neuromodulation devices, and pacemaker batteries. With expertise in medical device development and battery design, Integer serves various markets, providing innovative solutions to medical device OEMs. The company's brands, such as Greatbatch Medical® and Lake Region Medical®, have a strong reputation for delivering high-quality products. With a history of industry-changing innovations and manufacturing excellence, Integer continues to be a trusted partner in the medical device industry, offering expertise in cardiac rhythm, cardio and vascular health, neuromodulation, and portable power solutions.

Summarized from source with an LLMView SourceSector: Finance

Quarter (Q4 2025) results

Sales $472.1M (+5% vs. Q4 2024); GAAP operating income $56M (−2%); adjusted operating income $83M (+10%); GAAP income from continuing operations $49M (+47%); adjusted net income $62M (+22%); GAAP diluted EPS $1.38 (+52%); adjusted EPS $1.76 (+23%); adjusted EBITDA $106M (+11%); repurchased 698,356 shares for $50M.

Full year 2025

Sales $1.8536B (+8%); GAAP operating income $221M (+6%); adjusted operating income $321M (+13%); GAAP income from continuing operations $103M (−15%); adjusted net income $226M (+23%); GAAP diluted EPS $2.89 (−15%); adjusted EPS $6.40 (+21%); adjusted EBITDA $402M (+12%); operating cash flow $196M.

Product-line performance

Cardio & Vascular: Q4 $284.2M (+11%), FY $1.107B (+17%) — driven by acquisitions, neurovascular strength and EP ramps. Cardiac Rhythm Management & Neuromodulation: Q4 $167.3M (−2%), FY $668.8M (+1%) — neuromodulation softness from select emerging customers. Other Markets: Q4 $20.5M (−13%), FY $77.8M (−27%) due to the multi-year Portable Medical exit.

Balance sheet & liquidity

Total debt $1.185B (up $195M year-over-year); non‑GAAP net total debt $1.190B; leverage 3.0x trailing adjusted EBITDA. Cash and cash equivalents $17.2M at year end; 2025 capex $91M.

Share repurchase & capital actions

Completed repurchases of ~698k shares for $50M in the quarter and announced intent to commence an accelerated share repurchase (ASR) to repurchase approximately $50M more under the existing $200M authorization, to be funded by cash and borrowings.

2026 outlook

2026 GAAP sales guidance $1.826–1.876B (≈ flat year-over-year); GAAP diluted EPS $3.53–4.01 (up 22–39%); non‑GAAP adjusted EPS $6.29–6.78 (−2% to +6%); adjusted EBITDA $391–414M; cash from operations $200–220M; capex $95–105M; expected leverage 2.5–3.5x. Company reiterated expectation to return to ~200 bps above-market organic sales growth in 2027.

Non‑GAAP and reconciliation notes

Integer emphasizes adjusted measures (adjusted operating income, adjusted net income/EPS, adjusted EBITDA, organic sales) that exclude items such as amortization of intangibles, acquisition/integration costs, restructuring, ERP implementation and other discrete items; reconciliations are included in the release.

Summarized from source with an LLMView Source

Key figures

-24.7%1Y

12.2%3Y

-7.69%5Y

Performance

48.8%1Y

36.6%3Y

36.1%5Y

Volatility